Get the app
US › Healthcare

AN2 Therapeutics Inc (ANTX)

US · Healthcare · Biotechnology

$4.90-8.24%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-8.2M
EPS
$-0.18
EPS estimate
$-0.24

EPS came in at -0.18 against a street estimate of -0.24 — a beat of 25.0%.

Key statistics

Market cap
$203.8M
Forward P/E
0.0
P/B
2.66
Book value
$2.09
EPS (TTM)
$-1.05
52-week high
$7.19
52-week low
$1.00
50-day MA
$5.41
200-day MA
$3.52
Beta
-0.99

Analyst view

Analysts rate AN2 Therapeutics Inc a hold (1 buy, 1 hold, 1 sell out of 3) with an average price target of $9.00.

Shareholding

Insiders
18.13%
Institutions
76.55%

Largest institutional holders

FundStake
Vivo Capital, LLC8.36%
COMMODORE CAPITAL LP6.18%
Millennium Management LLC6.14%
Spruce Street Capital LP4.40%
Almitas Capital LLC3.92%
Vanguard Capital Management, LLC2.68%
Adage Capital Partners Gp LLC2.65%
Woodline Partners LP2.63%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for AN2 Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.